FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  KENYON LAWRENCE A					2. Issuer Name <b>and</b> Ticker or Trading Symbol Outlook Therapeutics, Inc. [OTLK]							(Check all applica  X Director  Y Officer (		Reporting able) give title	10% O re title Other (		ner	
(Last) (First) (Middle) C/O OUTLOOK THERAPEUTICS, INC. 4260 US ROUTE 1					3. Date of Earliest Transaction (Month/Day/Year) 07/17/2020						CEO, Pres, CFO, Treas & Secy							
(Street)  MONMO JUNCTIO	ON N	J state)	08852 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Ind Line)							
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				2. Transacti Date (Month/Day	Execution D		Date,	3. Transac Code (II					5. Amoun Securities Beneficial Owned Fo Reported	ly	Form:	Direct I Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount	(A) or (D)		ice	Transaction(s) (Instr. 3 and 4)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Executive Security or Exercise (Month/Day/Year) if any		3A. Deemed Execution Date if any (Month/Day/Ye	Pate, Transaction Code (Instr.				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)		Date Exercisable		xpiration ate	Title	Amo or Num of Sh	oer		(Instr. 4)	(5)		
Stock Option (Right to Buy)	\$1.58	07/17/2020		A		450,000		(1)	07	7/17/2030	Commor Stock	450	000	\$0.00	450,00	00	D	

## **Explanation of Responses:**

1. The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in four equal installments beginning on July 17, 2021 such that the option shall be vested in full on July 17, 2024, subject to the Reporting Person providing continuous service to the Issuer on each such date, and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

## Remarks:

/s/ Lawrence Kenyon

07/21/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.